Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16632
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDoyle, Adam-
dc.contributor.authorMarsh, Philip-
dc.contributor.authorGill, Raghubinder-
dc.contributor.authorRodov, Marcia-
dc.contributor.authorMohsen, Waled-
dc.contributor.authorVarma, Poornima-
dc.contributor.authorHong, Thai-
dc.contributor.authorStrasser, Simone I-
dc.contributor.authorBell, Sally-
dc.contributor.authorRyan, Marno-
dc.contributor.authorGow, Paul J-
dc.contributor.authorFink, Michael Anthony-
dc.contributor.authorRoberts, Stuart-
dc.contributor.authorKemp, William-
dc.contributor.authorKronborg, Ian-
dc.contributor.authorArachchi, Niranjan-
dc.contributor.authorKnight, Virginia-
dc.contributor.authorDev, Anouk-
dc.date2016-05-10-
dc.date.accessioned2017-04-27T03:44:23Z-
dc.date.available2017-04-27T03:44:23Z-
dc.date.issued2016-08-
dc.identifier.citationScandinavian Journal of Gastroenterology 2016; 51(8): 979-985en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16632-
dc.description.abstractOBJECTIVE: Sorafenib is an oral multikinase inhibitor that improves survival in advanced hepatocellular carcinoma (HCC). In the absence of alternative therapies, sorafenib is often continued despite advancing liver disease or tumour progression. Real world studies are important to better characterise outcomes in these populations. Our aim was to review patterns of sorafenib use across eight Australian tertiary hospitals, defining variables associated with clinical outcomes. MATERIAL AND METHODS: Retrospective cohort study of medical records of 320 patients treated with sorafenib for HCC. Baseline clinical parameters, dosage, adverse effects, and survival from initiation of treatment were collected. Time to radiological progression and 3-month alpha-fetoprotein (AFP) levels were available for a subset of patients. RESULTS: Adverse effects occurred in 79% of patients, requiring dose reduction in 31% of patients. Multivariate analysis identified an increased rate of mortality with Child-Pugh C (HR 5.52, p = 0.012), ECOG performance status 2-3 (HR 2.84, p = 0.001), and extrahepatic metastases (HR 1.54, p = 0.04), and decreased rate of mortality with an AFP reduction of at least 20% at 3 months (HR 0.38, p = 0.001). An increased rate of radiological progression was associated with ECOG performance status 2-3 (HR 2.34, p = 0.041), whilst a decreased rate of radiological progression was associated with development of on-treatment diarrhoea (HR 0.55, p = 0.015). CONCLUSIONS: Survival in patients with Child-Pugh C liver function or advanced functional impairment treated with sorafenib is poor and thus routine use of this agent in these patients does not appear justified, particularly given the high rate of adverse effects. AFP concentration on therapy may help identify favourable response to treatment.en_US
dc.subjectAdverse effectsen_US
dc.subjectMultivariate analysisen_US
dc.subjectProgressionen_US
dc.subjectSurvivalen_US
dc.titleSorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world studyen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleScandinavian Journal of Gastroenterologyen_US
dc.identifier.affiliationDepartment of Gastroenterology, Monash Health, Victoria, Australiaen_US
dc.identifier.affiliationAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Gastroenterology and Hepatology, Royal Melbourne Hospital, Victoria , Australiaen_US
dc.identifier.affiliationDepartment of Gastroenterology, St Vincent's Hospital, Victoria, Australiaen_US
dc.identifier.affiliationGastroenterology and Hepatologyen_US
dc.identifier.affiliationSurgeryen_US
dc.identifier.affiliationDepartment of Gastroenterology, Alfred Hospital, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Gastroenterology, Western Hospital, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27161568en_US
dc.identifier.doi10.3109/00365521.2016.1166518en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherGow, Paul J
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.